灌装-完成製药合约製造市场- 副产品（西林瓶[玻璃、塑胶]、预装注射器、药筒）、分子（大分子和小分子）、最终用途（生物製药和製药公司）、全球预测（2024 - 2032）

受製药公司为简化生产流程和降低营运成本而日益增长的外包趋势的推动，2024年至2032年，灌装药品合约製造市场规模的复合年增长率将达到6.2%。例如，2024 年 3 月，SMC Ltd. 收购了位于北卡罗来纳州夏洛特的一家灌装/加工工厂，以透过实验室到市场开发、设备製造和二次包装扩大为製药客户提供的服务。

配备先进技术和设施的合约製造商确保遵守严格的品质标准并遵守监管指南，包括良好生产规范 (GMP)。这种能力对于满足全球对高品质药品日益增长的需求以及应对复杂的国际市场也至关重要。

整个产业分为产品、分子、最终用途和区域。

从产品来看，由于对方便、安全的给药系统的需求不断增长，预充式註射器领域的灌装药品合约製造市场预计将成长到 2032 年。预充式註射器具有精确的剂量传递、降低污染风险和易于给药等优点，使其受到医疗保健提供者和患者的欢迎。专门从事灌装-完成服务的合约製造商也透过提供预灌封注射器无菌填充、组装和包装方面的专业知识来帮助满足这些需求。

就最终用途而言，製药公司领域的灌装医药合约製造市场将在 2024 年至 2032 年间录得显着增长，这将受到外包的青睐，以提高营运效率并专注于核心竞争力。製药公司越来越依赖 CMO 提供填充完成服务，以简化生产、缩短上市时间并有效管理成本。合约製造进一步为製药公司提供了无菌灌装、包装和监管合规的专业知识，有利于该细分市场的成长。

在医疗保健支出增加、人口成长和慢性病盛行率上升的推动下，预计到 2032 年，亚太地区灌装医药合约製造业规模将以惊人的速度成长。战略地理位置和基础设施的改善有利于更容易进入全球主要市场，从而增强在国际舞台上的竞争力。製药公司也不断扩大业务并投资创新药物配方，刺激了区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 医药外包趋势日益明显
    • 填充加工製造流程不断进步的技术
    • 药物配方的复杂性不断增加
  • 产业陷阱与挑战
    • 严格的监管问题
    • 来自内部製造的竞争
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 小瓶
  • 玻璃瓶
  • 塑胶瓶
• 预充式註射器 (PFS)
  • 玻璃PFS
  • 塑胶PFS
• 墨水匣
• 其他产品

第 6 章：市场估计与预测：按分子，2021 - 2032

• 主要趋势
• 大分子
• 小分子

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 生物製药公司
• 製药公司

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Eurofins Scientific
• Fresenius Kabi Contract Manufacturing
• MabPlex International Co. Ltd.
• Novartis AG
• Recipharm AB
• Societal CDMO
• Simtra BioPharma Solutions (Baxter International Inc.)
• Symbiosis Pharmaceutical Services

Fill-finish pharmaceutical contract manufacturing market size will depict 6.2% CAGR from 2024 to 2032, driven by the increasing outsourcing trend among pharmaceutical companies to streamline production processes and reduce operational costs. For instance, in March 2024, SMC Ltd. acquired a fill/finish facility in Charlotte, NC, for expanding services to pharma clients with lab-to-market development, device manufacture, and secondary packaging.

Contract manufacturers equipped with advanced technologies and facilities are ensuring adherence to stringent quality standards and compliance with regulatory guidelines, including Good Manufacturing Practices (GMP). This capability is also essential for meeting the increasing global demand for high-quality pharmaceutical products while navigating the complexities of international markets.

The overall industry is segmented into product, molecule, end-use and region.

Based on product, the fill-finish pharmaceutical contract manufacturing market from the prefilled syringes segment is set to grow up to 2032 due to the increasing demand for convenient and safe drug delivery systems. Prefilled syringes offer advantages, such as precise dosage delivery, reduced risk of contamination, and ease of administration, making them popular among healthcare providers and patients. Contract manufacturers specializing in fill-finish services also help in meeting these demands by providing expertise in sterile filling, assembly, and packaging of prefilled syringes.

With respect to end use, the fill-finish pharmaceutical contract manufacturing market from the pharmaceutical companies segment will record a notable growth rate between 2024 and 2032 favored by outsourcing to enhance operational efficiency and focus on core competencies. Pharmaceutical firms are increasingly relying on CMOs for fill-finish services to streamline production, reduce time-to-market, and manage costs effectively. Contract manufacturing further offers pharmaceutical companies access to specialized expertise in sterile filling, packaging, and regulatory compliance, favoring the segment growth.

Asia Pacific fill-finish pharmaceutical contract manufacturing industry size is anticipated to grow at an impressive pace through 2032 fueled by increasing healthcare expenditure, growing population, and the rising prevalence of chronic diseases. The strategic geographical location and infrastructure improvements are facilitating easier access to key global markets for enhancing the competitiveness on international stage. Pharmaceutical companies are also continuing to expand their operations and invest in innovative drug formulations, subsequently stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing trend of pharmaceutical outsourcing
    • 3.2.1.2 Rising technological advancements in fill-finish manufacturing processes
    • 3.2.1.3 Increasing complexity of drug formulations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory issues
    • 3.2.2.2 Competition from in-house manufacturing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Vials
  • 5.2.1 Glass vials
  • 5.2.2 Plastic vials
• 5.3 Prefilled syringes (PFS)
  • 5.3.1 Glass PFS
  • 5.3.2 Plastic PFS
• 5.4 Cartridges
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Molecule, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Large molecules
• 6.3 Small molecules

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Biopharmaceutical companies
• 7.3 Pharmaceutical companies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Boehringer Ingelheim International GmbH
• 9.2 Catalent Inc.
• 9.3 Eurofins Scientific
• 9.4 Fresenius Kabi Contract Manufacturing
• 9.5 MabPlex International Co. Ltd.
• 9.6 Novartis AG
• 9.7 Recipharm AB
• 9.8 Societal CDMO
• 9.9 Simtra BioPharma Solutions (Baxter International Inc.)
• 9.10 Symbiosis Pharmaceutical Services